Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS110 plus carboplatin/gemcitabine vs carboplatin/gemcitabine in advanced triple negative breast cancer
2015-000179-29Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lacnotuzumab in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Mar 2015; status: completed.
02
Drugs
lacnotuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-000179-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000179-29.